Altium Capital Management LLC Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Altium Capital Management LLC lessened its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 35.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 230,257 shares of the biotechnology company’s stock after selling 124,743 shares during the quarter. Altium Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $4,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of ARWR. Geode Capital Management LLC raised its position in Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after buying an additional 26,171 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Arrowhead Pharmaceuticals by 11.6% during the fourth quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company’s stock worth $525,000 after purchasing an additional 2,907 shares in the last quarter. Franklin Resources Inc. lifted its position in Arrowhead Pharmaceuticals by 9.4% in the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock valued at $373,000 after purchasing an additional 1,658 shares during the period. Empowered Funds LLC purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $268,000. Finally, Nordea Investment Management AB increased its position in Arrowhead Pharmaceuticals by 6.3% during the 4th quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company’s stock worth $2,463,000 after purchasing an additional 7,776 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ ARWR opened at $11.24 on Friday. The firm’s 50-day moving average is $15.41 and its two-hundred day moving average is $18.66. The company has a market capitalization of $1.54 billion, a PE ratio of -2.17 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ARWR. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley reiterated a “buy” rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $41.44.

Insider Activity

In other news, CEO Christopher Richard Anzalone sold 40,322 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $10.07, for a total value of $406,042.54. Following the completion of the transaction, the chief executive officer now owns 4,022,055 shares of the company’s stock, valued at $40,502,093.85. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 276,839 shares of company stock worth $4,054,176 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.